Adults 18 to 99, any sex, with Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With an Objective Response, Stable Disease, or Progressive DiseasePrimary· 5 months
An objective response is defined as a complete or partial response. A complete response is complete disappearance of all tumor by physical examination and radiographic studies and bone marrow involvement, if appropriate, for a minimum of four weeks. A partial response is a \> 50% reduction in the sum of the products of the greatest perpendicular diameters of all measurable lesions compared to the corresponding baseline evaluation, for a minimum of four weeks. Stable disease indicates \< 50% change in the sum of the products of the greatest perpendicular diameters of all measurable lesions comp
Complete Response
Group
Value
95% CI
Antineoplaston Therapy
0
Partial Response
Group
Value
95% CI
Antineoplaston Therapy
0
Stable Disease
Group
Value
95% CI
Antineoplaston Therapy
0
Progressive Disease
Group
Value
95% CI
Antineoplaston Therapy
1
Adverse events — posted to ClinicalTrials.gov
Time frame: 9 years, 4 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Current therapies for Non-Hodgkin's Lymphoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Non-Hodgkin's Lymphoma.
PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Non-Hodgkin's Lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Other trials of Antineoplaston therapy (Atengenal + Astugenal)
Trials testing the same drug.
NCT00003512 — Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
· Phase 2
· withdrawn
NCT00003522 — Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
· Phase 2
· terminated
NCT00003513 — Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
· Phase 2
· terminated
NCT00003515 — Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
· Phase 2
· terminated
NCT00003534 — Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
· Phase 2
· withdrawn
Other recruiting trials for Non Hodgkin Lymphoma
Currently open trials in the same condition.
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
· Phase 1, PHASE2
· recruiting
NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna
· Phase 4
· recruiting
NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
· Phase 1
· active not recruiting
NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
· Phase 1
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Burzynski Research Institute
Last refreshed: 22 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003498.